Business
Omada Health Reports Third Quarter 2025 Results
Revenue of $68 million, up 49%; 53% Member GrowthSignificant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDAAnnounces New GLP-1
About this update from Omada Health, Inc.
[{"type":"text","content":"Revenue of $68 million, up 49%; 53% Member GrowthSignificant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDAAnnounces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024Revenue of $68 million, up 49% compared with the third quarter of 2024Prescribing offering: announced plans to launch a new prescribing offering that will combine Omada’s evidence-based behavior change program with medication management for anti-obesity medications (AOMs), including GLP-1s; the offering will tailor support before, during, and after treatment–designed to help improve member health outcomes and the value of AOM spendClinical differentiation: published 30th peer-reviewed manuscript, which demonstrated significant cost savings from Omada’s Joint & Muscle Health program, and released data showing that members in the analysis largely maintained their weight one year after discontinuing GLP-1 therapy — an outcome that challenges widespread assumptions of inevitable post-medication weight gainOmada Meal Map: launched Meal Map, an AI-powered nutrition experience that focuses on nutrient quality rather than calorie counting, building on OmadaSpark, the AI-driven nutrition education tool introduced earlier this year “Our third quarter results demonstrate the strength of Omada’s multi-product platform in a moment of intense national focus on obesity-related chronic disease,” said Sean Duffy, Co-founder and CEO of Omada Health. “We also took important steps to deepen our innovation in GLP-1 care options and advance our AI capabilities, both aimed at delivering meaningful and sustainable outcomes for our members and cost savings for customers.” Other Third Quarter 2025 Financial Highlights Gross margin of 66%, up from 63% in the third quarter of 2024Non-GAAP gross margin of 68%, up from 65% in the third quarter of 2024Net loss of $3 million, compared with a net loss of $9 million in the third quarter of 2024Adjusted EBITDA of $2 million compared with an adjusted EBITDA loss of $5 million in the third quarter of 2024Cash and cash equivalents of $199 mil...